These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19889117)

  • 21. Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: A report of two cases.
    Prieto-García A; Álvarez-Perea A; Matito A; Sánchez-Muñoz L; Morgado JM; Escribano L; Álvarez-Twose I
    J Allergy Clin Immunol Pract; 2015; 3(3):456-8. PubMed ID: 25687289
    [No Abstract]   [Full Text] [Related]  

  • 22. Omalizumab as a therapeutic alternative for chronic urticaria.
    Callejas-Rubio JL; Sánchez-Cano D; Lara MA; Ortego-Centeno N
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):556. PubMed ID: 19055216
    [No Abstract]   [Full Text] [Related]  

  • 23. The appropriate omalizumab patient.
    Karpel J; Bukstein DA; LoNigro R
    Manag Care; 2007 May; 16(5):44-50, 56. PubMed ID: 17552338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart transplantation in a patient with systemic mastocytosis.
    Moro JA; Almenar L; Jarque I; Martinez-Dolz L; Hernández MD; Crespo M; Salvador A
    J Heart Lung Transplant; 2008 Jun; 27(6):689-91. PubMed ID: 18503972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab.
    Sands MF; Blume JW; Schwartz SA
    J Allergy Clin Immunol; 2007 Oct; 120(4):979-81. PubMed ID: 17931567
    [No Abstract]   [Full Text] [Related]  

  • 26. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.
    Magerl M; Staubach P; Altrichter S; Ardelean E; Krause K; Metz M; Weller K; Maurer M
    J Allergy Clin Immunol; 2010 Sep; 126(3):665-6. PubMed ID: 20673981
    [No Abstract]   [Full Text] [Related]  

  • 27. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.
    Brockow K; Jofer C; Behrendt H; Ring J
    Allergy; 2008 Feb; 63(2):226-32. PubMed ID: 18186813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of omalizumab on patients with chronic urticaria.
    Spector SL; Tan RA
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):190-3. PubMed ID: 17718108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaesthesia in patients with mastocytosis.
    Konrad FM; Schroeder TH
    Acta Anaesthesiol Scand; 2009 Feb; 53(2):270-1. PubMed ID: 19175585
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab and omalizumab in severe, refractory insulin allergy.
    Yong PF; Malik R; Arif S; Peakman M; Amiel S; Ibrahim MA; Gough A
    N Engl J Med; 2009 Mar; 360(10):1045-7. PubMed ID: 19264698
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis. Reply to: Anaphylactic Shock due to Isatuximab and Successful Desensitization.
    Hutten EM; Roeloffzen WW; Lambeck AJ; van den Born-Bondt T; Oude Elberink HN; van de Ven AAJ
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):214-216. PubMed ID: 38888584
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).
    Kanu A; Patel K
    Pediatr Pulmonol; 2008 Dec; 43(12):1249-51. PubMed ID: 19009619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of omalizumab in Aspergillus-associated airway disease.
    Pérez-de-Llano LA; Vennera MC; Parra A; Guallar J; Marin M; Asensio O; Ausin P; Borderías L; Fernández C; Granel C; Pérez-Pimiento A; Rubio M
    Thorax; 2011 Jun; 66(6):539-40. PubMed ID: 21398373
    [No Abstract]   [Full Text] [Related]  

  • 37. Omalizumab efficacy in a girl with atopic eczema.
    Caruso C; Gaeta F; Valluzzi RL; Romano A
    Allergy; 2010 Feb; 65(2):278-9. PubMed ID: 19796201
    [No Abstract]   [Full Text] [Related]  

  • 38. Effective treatment of refractory severe heat urticaria with omalizumab.
    Bullerkotte U; Wieczorek D; Kapp A; Wedi B
    Allergy; 2010 Jul; 65(7):931-2. PubMed ID: 19930230
    [No Abstract]   [Full Text] [Related]  

  • 39. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.